Table 3 Secondary outcomes during the study period
ESPB group (n = 30) | TAPB group (n = 30) | p-value | |
|---|---|---|---|
PACU duration, min | 65.8 ± 7.3 | 68.3 ± 10.6 | 0.293 |
Cumulative sufentanil consumption, μg | |||
0–24 h | 62 (61–65) | 66 (63–70) | < 0.001 |
24–48 h | 61 (60–61.2) | 61 (60–62) | 0.46 |
Time to ambulation, days | 4 (3–4) | 4 (3–5) | 0.056 |
Hospital stay, days | 7 (6–9) | 8 (7–10) | 0.037 |
Patient satisfaction score | 9 (8 ~ 9) | 8 (7–9) | 0.001 |
Time to first flatus, h | 41 (32.8–48) | 43.5 (34.8–56.3) | 0.2 |
Required rescue analgesic, n (%) | 3 (10) | 5 (16.7) | 0.706 |
PONV, n (%) | 9 (30) | 5 (16.7) | 0.222 |
Comprehensive Complication Index | 0 (0–8.7) | 8.7 (0–14.4) | 0.216 |
Reported block complications | 0 | 0 | 0.99 |